Spleen stiffness determined by spleen-dedicated device accurately predicted esophageal varices in cirrhosis patients.

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Chronic Disease Pub Date : 2023-11-03 eCollection Date: 2023-01-01 DOI:10.1177/20406223231206223
Jiqing Liu, Hangfei Xu, Weiyuan Liu, Hongmei Zu, Huiguo Ding, Fankun Meng, Jing Zhang
{"title":"Spleen stiffness determined by spleen-dedicated device accurately predicted esophageal varices in cirrhosis patients.","authors":"Jiqing Liu,&nbsp;Hangfei Xu,&nbsp;Weiyuan Liu,&nbsp;Hongmei Zu,&nbsp;Huiguo Ding,&nbsp;Fankun Meng,&nbsp;Jing Zhang","doi":"10.1177/20406223231206223","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The advantages of spleen stiffness in prediction of high-risk varices (HRV) in cirrhosis patients have been confirmed. Recently, a new device utilizing a 100 Hz probe dedicated to spleen stiffness measurement (SSM) was developed.</p><p><strong>Objectives: </strong>To validate the clinical applicability of SSM@100 Hz in predicting HRV by comparing it with other non-invasive tests (NITs).</p><p><strong>Design: </strong>A prospective cohort study.</p><p><strong>Methods: </strong>A total of 171 cirrhosis patients who underwent esophagogastroduodenoscopy (EGD) examination were included in this study. SSM using a 100 Hz probe and liver stiffness measurement using a 50 Hz probe were performed. Additionally, 22 healthy controls underwent spleen stiffness evaluation using the 100 Hz probe.</p><p><strong>Results: </strong>The failure rates of spleen stiffness examination in patients with cirrhosis and in healthy controls were 2.9% and 4.5%, respectively. The means of SSM values were 56.4 ± 21.6 and 13.8 ± 6.7 kPa in cirrhosis and controls. SSM increased proportionally with the severity of esophageal varices. The area under receiver operating characteristic (ROC) for spleen stiffness in predicting HRV was 0.881 (95% confidence interval 0.829-0.934), with a cutoff value of 43.4 kPa. The accuracy, false negative rate and EGD spare rate were 86.5%, 2.5% and 24.3%, respectively. For HRV prediction, SSM was comparable to expanded Baveno VI and VII and superior to other NITs. As to viral <i>versus</i> non-viral cirrhosis and compensated <i>versus</i> decompensated cirrhosis, the cut-off and performance of SSM were different.</p><p><strong>Conclusion: </strong>SSM@100 Hz demonstrates high accuracy in predicting HRV with a low missed HRV rate. Our findings suggest that SSM@100 Hz can be used independently due to its simplicity and effectiveness. However, further studies are needed to determine appropriate cutoff values based on the cause of cirrhosis and liver function.</p><p><strong>Trail registration: </strong>ChiCTR2300070270.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231206223"},"PeriodicalIF":3.3000,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623997/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231206223","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The advantages of spleen stiffness in prediction of high-risk varices (HRV) in cirrhosis patients have been confirmed. Recently, a new device utilizing a 100 Hz probe dedicated to spleen stiffness measurement (SSM) was developed.

Objectives: To validate the clinical applicability of SSM@100 Hz in predicting HRV by comparing it with other non-invasive tests (NITs).

Design: A prospective cohort study.

Methods: A total of 171 cirrhosis patients who underwent esophagogastroduodenoscopy (EGD) examination were included in this study. SSM using a 100 Hz probe and liver stiffness measurement using a 50 Hz probe were performed. Additionally, 22 healthy controls underwent spleen stiffness evaluation using the 100 Hz probe.

Results: The failure rates of spleen stiffness examination in patients with cirrhosis and in healthy controls were 2.9% and 4.5%, respectively. The means of SSM values were 56.4 ± 21.6 and 13.8 ± 6.7 kPa in cirrhosis and controls. SSM increased proportionally with the severity of esophageal varices. The area under receiver operating characteristic (ROC) for spleen stiffness in predicting HRV was 0.881 (95% confidence interval 0.829-0.934), with a cutoff value of 43.4 kPa. The accuracy, false negative rate and EGD spare rate were 86.5%, 2.5% and 24.3%, respectively. For HRV prediction, SSM was comparable to expanded Baveno VI and VII and superior to other NITs. As to viral versus non-viral cirrhosis and compensated versus decompensated cirrhosis, the cut-off and performance of SSM were different.

Conclusion: SSM@100 Hz demonstrates high accuracy in predicting HRV with a low missed HRV rate. Our findings suggest that SSM@100 Hz can be used independently due to its simplicity and effectiveness. However, further studies are needed to determine appropriate cutoff values based on the cause of cirrhosis and liver function.

Trail registration: ChiCTR2300070270.

Abstract Image

Abstract Image

Abstract Image

脾脏专用装置测定的脾脏硬度可准确预测肝硬化患者的食管静脉曲张。
背景:脾脏硬度在预测肝硬化患者高危静脉曲张(HRV)方面的优势已经得到证实。最近,一种利用100 研制了用于脾脏硬度测量(SSM)的Hz探头。目的:验证SSM@100 Hz通过与其他非侵入性测试(NIT)进行比较来预测HRV。设计:一项前瞻性队列研究。方法:本研究共纳入171例接受食管胃十二指肠镜检查的肝硬化患者。使用100的SSM Hz探头和使用50 Hz探头。此外,22名健康对照使用100 Hz探头。结果:肝硬化患者脾脏硬度检查失败率为2.9%,健康对照组为4.5%。SSM值的平均值为56.4 ± 21.6和13.8 ± 6.7 肝硬化和对照组的kPa。SSM与食管静脉曲张的严重程度成比例增加。脾脏硬度在预测HRV中的受试者操作特征面积(ROC)为0.881(95%置信区间为0.829-0.934),临界值为43.4 kPa。准确率为86.5%,假阴性率为2.5%,EGD备用率为24.3%。对于HRV预测,SSM与扩展的Baveno VI和VII相当,并优于其他NIT。对于病毒性肝硬化与非病毒性肝硬化以及代偿性肝硬化与失代偿性肝硬化,SSM的临界值和性能不同。结论:SSM@100 Hz在预测HRV时显示出高准确度,而漏诊HRV率较低。我们的研究结果表明SSM@100 Hz由于其简单有效而可以独立使用。然而,还需要进一步的研究来根据肝硬化和肝功能的原因来确定合适的临界值。试用注册:ChiCTR230070270。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)
CiteScore
6.20
自引率
0.00%
发文量
108
审稿时长
12 weeks
期刊介绍: Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信